Article
Biochemistry & Molecular Biology
Elisa Rubino, Andrea Marcinno, Alberto Grassini, Elisa Maria Piella, Fabio Ferrandes, Fausto Roveta, Silvia Boschi, Aurora Cermelli, Salvatore Gallone, Lidia Savi, Innocenzo Rainero
Summary: Migraine is a common disorder with unsatisfactory response to acute pain-relieving therapies. Functional polymorphism in the TNF-alpha gene is associated with the efficacy of NSAID administration.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Medicine, General & Internal
Raffaele Ornello, Eleonora De Matteis, Chiara Di Felice, Valeria Caponnetto, Francesca Pistoia, Simona Sacco
Summary: Menstrual migraine and perimenopausal migraine are distinct clinical entities influenced by female reproductive milestones, with treatment options including long-acting triptans, combination therapy, and hormone treatments. Future research should focus on the interaction between female sex hormones and the mechanisms of migraine pathogenesis.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Clinical Neurology
Marcy E. Yonker, Jennifer McVige, Leonid Zeitlin, Hester Visser
Summary: The study aimed to evaluate the efficacy and safety of ZNS nasal spray in the acute treatment of migraine in patients aged 6 to 11 years. The high-dose ZNS did not achieve statistical significance in pain-free status at 2 hours, but demonstrated good safety and tolerability in this pediatric population.
Article
Clinical Neurology
Diane Merino, Alexandre O. Gerard, Elise K. Van Obberghen, Alexandre Destere, Michel Lanteri-Minet, Milou-Daniel Drici
Summary: Migraine is the second leading cause of disability worldwide. Triptans are the first-line treatment, although discouraged for use in high cardiovascular risk individuals. Lasmiditan, a selective 5-HT1F agonist, is a potential emerging option. A safety profile analysis comparing lasmiditan with triptans found that neurological and psychiatric disorders were disproportionally reported with lasmiditan, while adverse drug reaction classes were reported with triptans. Neuropsychiatric signals persisted more with triptans compared to lasmiditan. These findings suggest that lasmiditan may be a safe alternative for migraine treatment.
Article
Medicine, General & Internal
Maria Pilar Navarro-Perez, Sara Ballesta-Martinez, Joana Rodriguez-Montolio, Elena Bellosta-Diago, Jose Alberto Garcia-Noain, Sonia Santos-Lasaosa
Summary: A majority of patients with migraine who present to the emergency department are women with a mean age of 34.9 years, and most of them have episodic migraine. A significant portion of patients had taken analgesics before visiting the ED. Common tests performed in the ED include blood tests and cranial CT, with NSAIDs, antiemetics, and metamizole being commonly used in treatment.
INTERNAL AND EMERGENCY MEDICINE
(2021)
Article
Clinical Neurology
Ilaria Frattale, Valeria Caponnetto, Alfonsina Casalena, Maurizio Assetta, Maurizio Maddestra, Fabio Marzoli, Giannapia Affaitati, Maria Adele Giamberardino, Stefano Viola, Amleto Gabriele, Francesca Pistoia, Davide Cerone, Carmine Marini, Simona Sacco, Raffaele Ornello
Summary: The study found that 80.2% of triptan users were triptan responders, while 63.7% were erenumab responders. The response to triptans was associated with the response to erenumab in the study, with a significant odds ratio for erenumab response in triptan users compared to non-users. Starting erenumab also improved triptan response in both erenumab responders and non-responders, suggesting potential benefits for migraine treatment.
JOURNAL OF HEADACHE AND PAIN
(2021)
Review
Pharmacology & Pharmacy
Rashid Giniatullin
Summary: 5-hydroxytryptamine (5-HT) is considered a key mediator in migraine, but the role of 5-HT3 receptors in pain transmission remains controversial. The applicability of currently available 5-HT3 antagonists in migraine treatment is not clearly supported by clinical data.
BRITISH JOURNAL OF PHARMACOLOGY
(2022)
Article
Clinical Neurology
Ali Ezzati, Dawn C. Buse, Kristina M. Fanning, Michael L. Reed, Vincent T. Martin, Richard B. Lipton
Summary: This study aimed to identify predictors of acute treatment optimization among people with episodic migraine. The results showed that men, individuals with higher average headache pain intensity, higher migraine symptom severity scores, presence of cutaneous allodynia, and depression had reduced odds of adequate 2-hour pain freedom response. Adequate 24-hour pain relief was associated with being married, but declined in those with higher-than-average average headache pain intensity and frequency, greater disability, presence of cutaneous allodynia, and depression. Participants taking triptans were more likely to have adequate treatment response compared to those taking butalbital combination medications (BCMs) and opioids. There was no significant difference in response to treatment between participants taking BCMs and opioids.
CLINICAL NEUROLOGY AND NEUROSURGERY
(2022)
Article
Clinical Neurology
Mateusz Chwolka, Peter J. Goadsby, Andreas R. Gantenbein
Summary: This study presents five patients for whom it was difficult to distinguish between migraine and cluster headache. These patients had phenotypic features that could be attributed to both disorders. A correct diagnosis is crucial for selecting the appropriate treatment approach, especially if initial treatment is not successful and further diagnostic and therapeutic options should be considered.
Article
Clinical Neurology
Matt Fisher, Abhay Aher, Mako Araga, Billy Franks
Summary: This study aimed to determine the association between oral sumatriptan dose preference and clinical or demographic factors. The results showed that no clinical or demographic characteristics were consistently or strongly associated with preference for oral sumatriptan dose level.
Article
Clinical Neurology
Holly M. Crowe, Amelia K. Wesselink, Lauren A. Wise, Susan S. Jick, Kenneth J. Rothman, Ellen M. Mikkelsen, Henrik T. Sorensen, Elizabeth E. Hatch
Summary: This study evaluates the association between pre-pregnancy migraine diagnosis and medication use with the risk of spontaneous abortion. The findings suggest that the use of certain migraine medications may increase the risk of spontaneous abortion.
JOURNAL OF HEADACHE AND PAIN
(2022)
Article
Engineering, Biomedical
Mahsa Babaei, Alan M. Rapoport
Summary: Nerivio is a wearable device that utilizes remote electrical neuromodulation to provide effective, tolerable, and safe treatment for migraine sufferers. It is user-friendly, affordable, non-addictive, and has been cleared by the FDA and the European Conformity. The article discusses the device's structure, mechanism of action, indications for use, application instructions, efficacy, adverse events, tolerability, safety, patient satisfaction, associated applications, and research highlights.
EXPERT REVIEW OF MEDICAL DEVICES
(2023)
Review
Clinical Neurology
Alison M. Deighton, Linda A. Harris, Karissa Johnston, Shomari Hogan, Lynn A. Quaranta, Gilbert L'Italien, Vlad Coric
Summary: The evidence suggests that rates of switch and discontinuation (WCS) among triptan users are low, with many patients opting for alternative acute medications after their first refill. Patients may not see improvement in disability when switching between triptans or turning to traditional acute migraine treatments. Variability in healthcare settings, patient severity, and study design contribute to the heterogeneity across the synthesis.
Review
Medicine, General & Internal
Maria Albanese, Nicola Biagio Mercuri
Summary: Recently, monoclonal antibodies (mAbs) targeting CGRP or its receptor have been approved for prophylactic use in migraine. While their efficacy in treating headache pain is well-documented, little is known about their effects on preventing migraine aura. This paper reports two cases of patients experiencing complete disappearance or reduction of aura symptoms when taking Galcanezumab or Erenumab, respectively. It also provides an overview of the controversial relationship between cerebral spreading depression and CGRP, as well as the potential central role of these mAbs in the pathophysiology of migraine aura.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Clinical Neurology
Karin Zebenholzer, Walter Gall, Andreas Gleiss, Antun R. Pavelic, Christian Woeber
Summary: This study investigated the vascular comorbidity in users and nonusers of triptans over the age of 50. The results showed that there was no significant difference in vascular comorbidity between the two groups, suggesting that triptan use does not increase vascular risk in patients with migraine over the age of 50. However, regular evaluation for contraindications and vascular risk factors is still recommended in this age group.